Third Rock Ventures is a venture capital firm that invests in biotechnology startups. They asked us to tell the genesis story of 2015 IPO star Global Blood Therapeutics, a company it founded. As we dug deeper, the Bluedeeno team discovered that GBT treats Sickle Cell, a historically underfunded disease that affects an underserved population. Our short doc not only showcased GBT’s financial success and TRV’s management acumen – but we also told a feel-good story about a company helping a group of people who desperately need it. The client loved it, and so did their investors who watched it on the big screen at TRV’s high-profile annual meeting.